No results for ‘’
Aspira Pathlab & Diagnostics Ltd
₹131.25
(4.74%)
Fri, 02 Oct 2026, 07:15 pm
Health Services
Medical/Nursing Services
24.5KAspira Pathlab & Diagnostics Ratios
| Particulars | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 19.65 | 14.96 | 0 | 0 | 43.37 |
| Price to book ratio | 0 | 26.34 | 85.65 | 0 | 8.67 | 5.22 | 2.25 | 3.15 | 7.21 |
| Price to sales ratio | 0 | 2.02 | 2.50 | 3.90 | 1.78 | 3.41 | 1.98 | 2.42 | 3.99 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 5.44 | 38.05 | 228.78 | 24.79 | 43.33 |
| Enterprise value | 0 | 19.95Cr | 31.55Cr | 45.54Cr | 32.96Cr | 68.98Cr | 29.63Cr | 33.31Cr | 88.78Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 9.38 | 10.82 | 18.60 | 0 | 24.96 |
| Debt to equity ratio | 1.23 | 33.92 | 1.46 | 2.34 | 0.25 | 0.31 | 0.26 | 0.27 | 0.26 |
| Return on equity % | 0 | -179.71 | -187.57 | -94.32 | 22.80 | 42.26 | -0.69 | -23.34 | 18.13 |
Aspira Pathlab & Diagnostics Ltd Ratios
The Aspira Pathlab & Diagnostics Ltd Ratios page provides a complete fundamental analysis of Aspira Pathlab & Diagnostics Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Aspira Pathlab & Diagnostics Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Aspira Pathlab & Diagnostics Ltd (NSE: , BSE: 540788) is currently trading at ₹131.25, with a market capitalization of ₹135.1Cr. As a major player in the Health services sector and Medical/Nursing services industry, Aspira Pathlab & Diagnostics Ltd remains a key stock for fundamental analysis using Aspira Pathlab & Diagnostics Ltd Ratios.
Aspira Pathlab & Diagnostics Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Aspira Pathlab & Diagnostics Ltd P/E ratio currently stands at 43.37, making it one of the most tracked metrics in Aspira Pathlab & Diagnostics Ltd Ratios.
Historically, the Aspira Pathlab & Diagnostics Ltd P/E ratio has shown strong fluctuations:
- 2024: 43.37
- 2023: 0
- 2022: 0
- 2021: 14.96
- 2020: 19.65
The rising Aspira Pathlab & Diagnostics Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Aspira Pathlab & Diagnostics Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 7.21.
Historical P/B trend:
- 2024: 7.21
- 2023: 3.15
- 2022: 2.25
- 2021: 5.22
Aspira Pathlab & Diagnostics Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Aspira Pathlab & Diagnostics Ltd P/S ratio currently stands at 3.99, an important part of Aspira Pathlab & Diagnostics Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 3.99
- 2023: 2.42
- 2022: 1.98
- 2021: 3.41
The rising Aspira Pathlab & Diagnostics Ltd P/S ratio indicates improved revenue valuation by investors.
Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio (P/CF)
The Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 43.33.
Historical Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio:
- 2024: 43.33
- 2023: 24.79
- 2022: 228.78
- 2021: 38.05
- 2020: 5.44
The rising Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Aspira Pathlab & Diagnostics Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Aspira Pathlab & Diagnostics Ltd EV currently stands at ₹88.78Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 88.78Cr
- 2023: 33.31Cr
- 2022: 29.63Cr
- 2021: 68.98Cr
Aspira Pathlab & Diagnostics Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Aspira Pathlab & Diagnostics Ltd EV/EBITDA ratio is currently 24.96, a key metric in Aspira Pathlab & Diagnostics Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 24.96
- 2023: 0
- 2022: 18.60
- 2021: 10.82
Higher Aspira Pathlab & Diagnostics Ltd EV/EBITDA suggests premium valuation.
Aspira Pathlab & Diagnostics Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Aspira Pathlab & Diagnostics Ltd D/E ratio is currently 0.26, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.26
- 2023: 0.27
- 2022: 0.26
- 2021: 0.31
Aspira Pathlab & Diagnostics Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Aspira Pathlab & Diagnostics Ltd ROE currently stands at 18.13%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 18.13
- 2023: -23.34
- 2022: -0.69
- 2021: 42.26
Aspira Pathlab & Diagnostics Ltd maintains stable profitability levels.
Aspira Pathlab & Diagnostics Ltd Ratios Analysis Summary
The Aspira Pathlab & Diagnostics Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Aspira Pathlab & Diagnostics Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Aspira Pathlab & Diagnostics Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.